2-(氯甲基)苯并[b]噻吩 | 2076-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 2-(氯甲基)苯并[b]噻吩
• 中文别名: 2-(氯甲基)苯并噻吩；2-(氯甲基)-1-苯并噻吩
• 英文名称: 2-chloromethylbenzo[b]thiophene
• 英文别名: 2-chloromethylbenzothiophene；2-(chloromethyl)benzothiophene；2-(Chloromethyl)-1-benzothiophene
• CAS: 2076-88-2
• 化学式: C₉H₇ClS
• mdl: MFCD08060638
• 分子量: 182.674
• InChiKey: JHDSVVPTMIYVGV-UHFFFAOYSA-N

物化性质

• 熔点：
  44-45 °C
• 沸点：
  129-131 °C(Press: 5 Torr)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P310,P330,P332+P313,P362,P403+P233,P405,P501
• 危险品运输编号：
  3261
• 危险性描述：
  H302,H315,H318,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  2-(氯甲基)苯并[b]噻吩 在 镍 氢气 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 生成 N-[3-[(2-Benzo[b]thienyl)methoxy]phenyl]ethane sulfonamide
  参考文献：
  名称：

  N-[(Arylmethoxy)phenyl] and N-[(arylmethoxy)naphthyl] sulfonamides: potent orally active leukotriene d4 antagonists of novel structure

  摘要：

  Two series of compounds, N-[(arylmethoxy)phenyl] sulfonamides and N-[(arylmethoxy)naphthyl] sulfonamides, were prepared as leukotriene D4 (LTD4) antagonists. In the phenyl series, N-[3-(2-quinolinylmethoxy)phenyl]-trifluoromethanesulfonamide (Wy-48,252, 16) was the most potent inhibitor of LTD4-induced bronchoconstriction in the guinea pig. With an intragastric ID50 of 0.1 mg/kg (2-h pretreatment), 16 was 300 times more potent than LY-171,883. Compound 16 also intragastrically inhibited ovalbumin-induced bronchoconstriction in the guinea pig with an ID50 of 0.6 mg/kg. In vitro against LTD4-induced contraction of isolated guinea pig trachea pretreated with indomethacin and L-cysteine, 16 produced a pKB value of 7.7. In the rat PMN assay 16 inhibited both 5-lipoxygenase and cyclooxygenase (IC50's = 4.6 and 3.3 microM). In the naphthyl series, N-[7-(2-quinolinylmethoxy)-2-naphthyl]trifluoromethanesulfonamide (Wy-48,090, 47) in addition to potent LTD4 antagonist activity (on isolated guinea pig trachea 47 had a pKB value of 7.04) also had antiinflammatory activity (63% inhibition at 50 mg/kg in the rat carrageenan paw edema assay and 34% inhibition of TPA-induced inflammation at 1 mg/ear in the mouse ear edema model). Perhaps the antiinflammatory activity of 47 was due to its additional activity of inhibiting both 5-lipoxygenase and cyclooxygenase enzymes (IC50's = 0.23 and 11.9 microM, respectively, in rat PMN).

  DOI：

  10.1021/jm00126a006
• 作为产物：
  描述：

  1-苯并噻酚-2-羧醛 在 T406石油添加剂 、 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-(氯甲基)苯并[b]噻吩
  参考文献：
  名称：

  杂芳基丙烯酸酯和丙氨酸与欧芹中的苯丙氨酸氨裂解酶的相互作用。

  摘要：

  合成了在β位置被杂芳基取代的丙烯酸和丙氨酸，并进行了光谱表征（UV，HRMS，（1）H NMR和（13）C NMR光谱）。杂芳基基团是呋喃基，噻吩基，苯并呋喃基和苯并噻吩基，并且在2-或3-位含有丙酰基侧链。前者是苯丙氨酸解氨酶（PAL）的良好底物，而后者是抑制剂。例外的是噻吩-3-基丙氨酸（一种中等的底物）和呋喃-3-基丙氨酸（惰性）。讨论了这些例外的可能原因。从外消旋杂芳基-2-丙氨酸开始，它们的D-对映异构体通过立体破坏方法制备。由杂芳基-2-丙烯酸酯以高氨浓度制备杂芳基-2-丙氨酸的L-对映异构体。

  DOI：

  10.1002/chem.200501034

文献信息

• Photoinduced <scp>NaI‐Promoted</scp> Radical Borylation of Alkyl Halides and Pseudohalides
  作者：Chenglan Wang、Lu Zhou、Kai Yang、Feng Zhang、Qiuling Song

  DOI：10.1002/cjoc.202100115

  日期：2021.7

  A method for photoinduced NaI-promoted radical borylation of aliphatic halides and pseudohalides with bis(catecholato)diboron (B2cat2) as the boron source is introduced. The borylation reaction is operationally simple and shows high functional group tolerance and broad substrate scope. Preliminary mechanistic studies suggest that the reaction proceeds through SN2-based radical-generation strategy.

  介绍了一种以双(儿茶酚)二硼(B 2 cat 2 )为硼源的光诱导NaI促进的脂肪族卤化物和拟卤化物自由基硼化的方法。硼酸化反应操作简单，显示出高官能团耐受性和广泛的底物范围。初步机理研究表明，该反应通过基于S N 2 的自由基生成策略进行。
• Pyrimidine-thioalkyl and alkylether compounds
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1247804A1

  公开（公告）日：2002-10-09

  The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I and pyrimidine-thioalkyl and alkylethers of Formula IA, namely the compounds of Formula I where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -Cl); with the overall provisio that R4 and R6 are not both -H; The compounds of Formula IA are useful in the treatment of individuals who are HIV positive.

  该发明涉及Formula I的嘧啶硫代烷基和烷基醚化合物，以及Formula IA的嘧啶硫代烷基和烷基醚化合物，即Formula I中R4选自-H或-NR15R16的基团，其中R15为-H，R16为-H，C1-C6烷基，-NH2或R15和R16一起与-N形成1-吡咯啉基、1-吗啉基或1-哌啶基；以及R6选自-H或卤素（优选-Cl）的基团，总体规定是R4和R6不能同时为-H；Formula IA的化合物在治疗HIV阳性个体中是有用的。
• Anti-infective agents
  申请人：——

  公开号：US20040087577A1

  公开（公告）日：2004-05-06

  Compounds having the formula 1 are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

  具有公式1的化合物是丙型肝炎（HCV）聚合酶抑制剂。还公开了一种用于抑制丙型肝炎（HCV）聚合酶的组成和方法，用于制造这些化合物的过程，以及在这些过程中使用的合成中间体。
• [EN] SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS<br/>[FR] COMPOSES HETEROARYLE ET PHENYLSULFAMOYLE SUBSTITUES
  申请人：PFIZER PROD INC

  公开号：WO2005092845A1

  公开（公告）日：2005-10-06

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯基磺酰胺化合物，含有这种化合物的药物组合物以及将这种化合物用作过氧化物酶增殖激活受体（PPAR）激动剂的用途。PPARα激活剂，含有这种化合物的药物组合物以及使用这种化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中。这些化合物还可用于治疗反常能量平衡（NEB）和反常相关疾病的反刍动物。
• [EN] AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE UTILES POUR LE TRAITEMENT DE MALADIES MÉTABOLIQUES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2012098033A1

  公开（公告）日：2012-07-26

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病，举例不限。